Many studies demonstrated that statins, the HMGCR inhibitors, might protect against the development and recurrence of HCC (Friedman et al., 2016; Kim et al., 2018; German et al., 2020; Tran et al., 2020). Here, HMGCR is linked to hepatocellular carcinoma.